Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Study shows that ankylosing spondylitis can be predicted by low birth weight

Study shows that ankylosing spondylitis can be predicted by low birth weight

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Researchers explore benefits and risks of biosimilar antibodies

Researchers explore benefits and risks of biosimilar antibodies

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.